Article Sidebar

Submitted
26 July 2017
Accepted
26 July 2017
Published
8 August 2017
Download
PDF
Statistic
Read Counter : 4019 Download : 4405

Main Article Content

Abstract

Pneumonia is an infection of the lungs that occurs and still cause high mortality in young children today. The main cause is bacterial or viral. Antibiotics still recommended though it is difficult to know the cause is bacterial or viral. Ampicillin be the first option some guideline. Increased resistance worldwide become one of them concerns the effectiveness of antibiotics. The main treatment of toddler pneumonia in Muhammadiyah Hospital Lamongan are ampicillin sulbactam and cefotaxime. The study was conducted to analyze the effectiveness of both antibiotics. This study aims to analyze comparison in the use of ampicillin sulbactam and cefotaxime pneumonia patients aged 3-59 months from November 2013 to March 2014. Patients who met the inclusion criteria were prospectively observed for clinical data, laboratory data, the data microbiology. After it is analyzed to know the difference between the effectiveness of antibiotics. In this study of 29 patients included in the inclusion criteria, 17 patients who received antibiotics ampicillin sulbactam and 12 patients receiving cefotaxime. In the comparison of the mean pulse pulse is known there is a significant reduction in both groups of patients on the second day and was not significantly different between the two groups (p = 0.084). Likewise, the average ratio of temperature (p = 0.117), breath rate (p = 0.839), leukocytes of patients (p = 0.429). Length of stay for ampicillin sulbactam group was 4.77 days and 5.17 days for cefotaxime group. Analysis showed no differences between the two groups for lenght (p = 0.275). Of the 22 patients who were sampled for blood culture examination only 1 patient with positive results. Based on these results we can conclude that ampicillin sulbactam and cefotaxime effective in cases of children pneumonia, and there is no distinction based on the parameters in body temperature, breath rate, pulse, leukocytes and long hospitalization of patients. Regimentation dosage is appropriate based on guidelines, and length of stay less than 10 days. Found no side effects of both drugs.

Keywords

drug effectiveness pneumonia antibiotics ampicillin sulbactam cefotaxime

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Puspitasari, D., Hasmono, D., & Rahman, T. (2017). AMPICILLIN SULBACTAM AND CEFOTAXIME ARE SIMILARLY EFFECTIVE IN PEDIATRIC PNEUMONIA. Folia Medica Indonesiana, 52(2), 116–121. https://doi.org/10.20473/fmi.v52i2.5225
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Bradley JS and McCracken GH (2008). Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia. Clinical Infectious Disease 47, S241-S247
  2. Dalimunthe W, Daulay RS, Daulay RM (2013). Significant clinical features in pediatric pneumonia. Paediatrica Indonesiana 53, 37-40
  3. Harris M, Clark J, Coote N, Flether P, Harnden A, McKean M, Thomson A, On behalf of the British Thoracic Society Standards of Care Committee (2011). British thoracic society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 66, ii23
  4. Hazir T, Begum K, el Arifeen S, Khan AM, Huque MH, Kazmi N, Roy S, Abbasi S, Rahman QS, Theodoratou E, Khorshed MS, Rahman KM, Bari S, Kaiser MMI, Saha SK, Ahmed ASMNU, Rudan I, Bryce J, Qazi SA, Campbell H (2013). Measuring coverage in MNCH: a prospective validation study in Pakistan and Bangladesh on measuring correct treatment of childhood pneumonia. PLoS Med 10, e1001422
  5. Inoue M, Kohno S, Kaku M, Yamaguchi K, Igari J, Yamanaka K (2005). PROTEKT 1999”2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan. International Journal of Infectious Diseases 9, 27-36
  6. Katona P and Katona-Apte J (2008). The interaction between nutrition and infection. Clinical Infectious Diseases 46, 1582-1588
  7. Peltola H, Vuori-Holopainen E, Kallio MJT, The SE-TU Study Group (2001). Successful shortening from seven to four days of parenteral beta-lactam treatment for common childhood infections: a prospective and randomized study. International Journal of Infectious Diseases 5, 3-8
  8. Sandora TJ and Sectish TC (2011). Community acquired pneumonia. In: Kliegman RM, Stanton BMD, St Geme J, Schor NF, Behrman RE (eds). Nelson Textbook of Pediatrics, 19th ed, Philadelphia, Saunders, chapter 392
  9. Schaible UE and Kaufmann SHE (2007). Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 4, e115
  10. WHO (2010). Revised WHO classification and treatment of schilhood penumonia at health facilities. Availbale from http://apps.who.int/iris/bitstream/ 10665/137319/1/9789241507813_eng.pdf. Accessed Oktober 2, 2014

Most read articles by the same author(s)